Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327021 | 0.92 | SIGMAR1 (0.64) | SIGMAR1ALDH1A1MAPK1GFERKMT2A | |
| SCHEMBL3322300 | 0.91 | USP2 (0.70) | SIGMAR1ALDH1A1MAPK1GFERKMT2A | |
| SCHEMBL3387320 | 0.90 | SIGMAR1 (0.61) | SIGMAR1ALDH1A1MAPK1GFERKMT2A | |
| SCHEMBL3326549 | 0.89 | SIGMAR1 (0.59) | SIGMAR1ALDH1A1MAPK1GFERKMT2A | |
| SCHEMBL3326554 | 0.89 | SIGMAR1 (0.59) | SIGMAR1ALDH1A1MAPK1GFERKMT2A | |
| SCHEMBL1674212 | 0.87 | SIGMAR1 (0.74) | SIGMAR1ALDH1A1MAPK1GFERKMT2A | |
| SCHEMBL3387282 | 0.86 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1MAPK1GFERKMT2A | |
| SCHEMBL3326595 | 0.86 | SIGMAR1 (0.55) | SIGMAR1ALDH1A1MAPK1GFERKMT2A | |
| SCHEMBL6034681 | 0.85 | SIGMAR1 (1.00) | SIGMAR1ALDH1A1MAPK1GFERKMT2A | |
| SCHEMBL3324307 | 0.85 | HSD17B10 (0.67) | SIGMAR1ALDH1A1MAPK1GFERCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142499-B1 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma | UNIMED PHARMA SPOL SRO (SK) | 2014-12-10 | — | — | EP | claimed |
| US-8193184-B2 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use | Unimed Pharma, SPOL, S.R.O. (SK) | 2012-06-05 | — | — | US | claimed |
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2010-05-20 | — | — | US | claimed |
| EP-2142499-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | Unimed Pharma, Spol. S R.O. (SK) | 2010-01-13 | — | — | EP | claimed |
| WO-2008130332-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2008-10-30 | — | — | WO | claimed |
| EP-2142499-B1 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use for treating glaucoma | UNIMED PHARMA SPOL SRO (SK) | 2014-12-10 | — | — | EP | disclosed |
| US-8193184-B2 | Substituted sulphonamides, process for their preparation, pharmaceutical composition comprising thereof and their use | Unimed Pharma, SPOL, S.R.O. (SK) | 2012-06-05 | — | — | US | disclosed |
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2010-05-20 | — | — | US | disclosed |
| EP-2142499-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | Unimed Pharma, Spol. S R.O. (SK) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008130332-A1 | SUBSITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | UNIMED PHARMA, SPOL. S R.O. (SK) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125076-A1 | SUBSTITUTED SULPHONAMIDES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND THEIR USE | ARSA, SMS, SULT1E1 | SIGMAR1 128/4885ALDH1A1 967/4885MAPK1 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.